NCT06335251 Radiotherapy Treatments for Neoplasms of the Limbs
| NCT ID | NCT06335251 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Bone Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2018-02-22 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2018-02-22 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this observational study patients treated at European Institute of Oncology with radiotherapy to limbs will be included
Eligibility Criteria
Inclusion Criteria: 1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the upper and lower limbs for: Primary bone tumors, Primary soft tissue tumors, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system and skin, Secondary metastases from various origins localized in that district. 2. Signed informed consent Exclusion Criteria: 1\. Radiotherapy in districts other than limbs.
Contact & Investigator
Barbara Alicja Jereczek
PRINCIPAL INVESTIGATOR
European Institute of Oncology
Frequently Asked Questions
Who can join the NCT06335251 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bone Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06335251 currently recruiting?
Yes, NCT06335251 is actively recruiting participants. Contact the research team at barbara.jereczek@ieo.it for enrollment information.
Where is the NCT06335251 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06335251 clinical trial?
NCT06335251 is sponsored by European Institute of Oncology. The principal investigator is Barbara Alicja Jereczek at European Institute of Oncology. The trial plans to enroll 3,000 participants.